{"title":"Effects of Auto-Titrating Mandibular Advancement Device on Autonomic Nervous System in Obstructive Sleep Apnea.","authors":"Dae-Soon Son, Jae-In Kim, Dong-Kyu Kim","doi":"10.3390/jpm14121151","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives:</b> One prior study revealed that a newly developed auto-titrating mandibular advancement device (AMAD) could potentially enhance polysomnographic outcomes in individuals with obstructive sleep apnea (OSA). However, evidence regarding its impact on autonomic nervous system dysregulation in OSA remains limited. In this study, we aimed to compare the effects of conventional mandibular advancement devices (MADs) and AMDA on autonomic function. <b>Methods</b>: We retrospectively reviewed data from patients who visited a sleep center with complaints of snoring and sleep apnea (30 and 15 patients in the conventional MAD and AMAD groups, respectively). We assessed heart rate variability (HRV) frequency-domain metrics such as total power (TP), very low frequency (VLF), low frequency (LF), and high frequency (HF) using ultra-short-term and short-term modalities, assessing sympathetic and parasympathetic activity changes across treatment groups. <b>Results</b>: Conventional MAD treatment was associated with reductions in LF and LF/HF ratios, whereas AMAD treatment was linked to decreases in TP, VLF, LF, and LF/HF ratios. Notably, in patients with moderate OSA, LF values were significantly lower in the AMAD group than in the conventional MAD group. <b>Conclusions</b>: These findings suggest that both devices could reduce sympathetic over-activity in patients with OSA, with AMAD demonstrating greater efficacy, particularly in those with moderate OSA.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"14 12","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680007/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm14121151","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background/Objectives: One prior study revealed that a newly developed auto-titrating mandibular advancement device (AMAD) could potentially enhance polysomnographic outcomes in individuals with obstructive sleep apnea (OSA). However, evidence regarding its impact on autonomic nervous system dysregulation in OSA remains limited. In this study, we aimed to compare the effects of conventional mandibular advancement devices (MADs) and AMDA on autonomic function. Methods: We retrospectively reviewed data from patients who visited a sleep center with complaints of snoring and sleep apnea (30 and 15 patients in the conventional MAD and AMAD groups, respectively). We assessed heart rate variability (HRV) frequency-domain metrics such as total power (TP), very low frequency (VLF), low frequency (LF), and high frequency (HF) using ultra-short-term and short-term modalities, assessing sympathetic and parasympathetic activity changes across treatment groups. Results: Conventional MAD treatment was associated with reductions in LF and LF/HF ratios, whereas AMAD treatment was linked to decreases in TP, VLF, LF, and LF/HF ratios. Notably, in patients with moderate OSA, LF values were significantly lower in the AMAD group than in the conventional MAD group. Conclusions: These findings suggest that both devices could reduce sympathetic over-activity in patients with OSA, with AMAD demonstrating greater efficacy, particularly in those with moderate OSA.
期刊介绍:
Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.